Welcome to OM Pharma
Doxium® : Chronic venous insufficiency - Diabetic retinopathy
  Philosophy
  History
  Worldwide activity
  R & D
  Manufacturing
  Products
    Marketing Authorizations
    International Availability
  Main Products
    - Broncho-Vaxom
    - Dicynone
    - Doxium
    - Uro-Vaxom
    Other Products
    - Doxiproct
    - Doxiproct Plus
    - Gynazole
    - Sinomarin
  Health and Diseases
  News
  Contacts
  Careers and jobs
  Forum


  homepage > products doxium > pharmacokinetics
   
  Doxium
 
Pharmacokinetics

After oral administration of 500 mg of calcium dobesilate, its blood level is above 6 µg/ml between the 3rd and 10th hour, with a maximum (Cmax) of 8 µg/ml on the average after 6 hours (tmax). Twenty four hours after intake blood level is about 3 µg/ml. The rate of protein-binding is 20 - 25 %.

In animals, calcium dobesilate does not cross the haematoencephalic or the placental barrier, but it is not known whether this is also the case in humans. Calcium dobesilate enters the maternal milk in very low quantities (0,4 µg/ml after intake of 1500 mg as observed in one study).

Calcium dobesilate does not enter the enterohepatic cycle and is excreted mainly unchanged with only 10 % being excreted as metabolites.
About 50 % of the orally administered dose are eliminated in the first 24-hour urine and about 50 % in the faeces.
Plasma half-life is around 5 hours.

Kinetics in particular clinical situations
It is not known to what extent renal function disorders influence the pharmacokinetic properties of calcium dobesilate (see "Precautions").
  Contact us   back home